Voyager Therapeutics Q4 2022 Earnings Report
Key Takeaways
Voyager Therapeutics reported a net loss of $23.6 million for the fourth quarter of 2022, compared to a net income of $5.7 million for the same period in 2021. The negative collaboration revenue during the fourth quarter of 2022 was due to an increase in the estimate of the total expected cost of Voyager’s research services related to the 2019 collaboration with Neurocrine Biosciences.
Reprioritized high-value neurology pipeline and validated TRACERTM novel capsid platform through transactions with Pfizer and Novartis.
Partnering momentum continues into 2023 with $175 million payment associated with Neurocrine Biosciences strategic collaboration followed by $25 million payment triggered by Novartis capsid license option exercise.
Development candidate selected in tau antibody program for Alzheimer’s disease; development candidate selection in gene therapy program for ALS expected in H1 2023; expected IND filings for both programs on track for 2024.
Voyager initiates new early research initiative combining an siRNA tau knockdown payload with an intravenously delivered TRACER capsid for Alzheimer’s disease.